Evolution of innovation management approaches in the R&D of pharmaceutical industry
https://doi.org/10.24182/2073-6258-2026-25-2-73-83
Abstract
The article examines the evolution of management models in the innovative research and development (R&D) sector of the pharmaceutical industry. The relevance of the research is determined by the need to find effective approaches to overcoming the systemic contradiction in the management of pharmaceutical innovative R&D, where exponential growth of investments is accompanied by a decrease in the return on innovation, while simultaneously solving the tasks set by the Government of the Russian Federation within the framework of the Pharmaceutical Industry Development Strategy of the Russian Federation «Pharma–2030» to achieve technological sovereignty and ensure national security in the field of drug provision. This requires an accelerated transition from an import–dependent model to the creation of a full cycle of development and production of original medicines 2. The paper provides an analysis of the evolution of approaches to managing high–risk innovative pharmaceutical R&D projects. Four main stages in the evolution of management approaches are identified, their key parameters are determined, such as the concept of the management model and their costs, and a consistent transition from rigid linear to flexible digital models of innovation management is revealed. The determinants of the transition from classical linear models to modern models are identified. A key factor in the shift in management paradigms in pharmaceutical R&D is formulated as an increase in transaction costs caused by the need for data integration and adaptation in the context of increasingly complex innovation processes. The practical significance of the study lies in the proposal of criteria for the strategic choice of a management model for pharmaceutical innovative R&D, where the choice should be based on a multi–factor assessment of R&D stages, technological maturity and types of risks, which will allow organizations to minimize transaction costs through the adaptation of management practices.
About the Authors
K. R. RakhmanovaRussian Federation
postraduate student
Saint Petersburg
А. А. Gorovoy
Russian Federation
Dr. Sci. (Econ.), Prof.
Saint Petersburg
References
1. Laermann-Nguyen, U., & Backfisch, M. (2021). Innovation crisis in the pharmaceutical industry? A survey. SN Business & Economics, 1(12), 164.
2. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of health economics, 47, 20–33.
3. Peralta, G., & Sбnchez, B. (2025). Driving health transformation: big pharma’s innovation labs revolution. Health Research Policy and Systems, 23(1), 138.
4. MANDALITI, D. (2024). Global Innovation Networks in the pharmaceutical Industry: evolution of pharmaceutical R&D and impact on innovation processes.
5. Klunko N.S. (2014). Adaptation to external environmental conditions as a factor of improving the effectiveness of modern pharmaceutical complex of Russia. Regional Problems of Economic Transformation., 4 (42), 33–40 (In Russ.).
6. Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery, 11(3), 191–200.
7. Blau, G. E., Pekny, J. F., Varma, V. A., & Bunch, P. R. (2004). Managing a portfolio of interdependent new product candidates in the pharmaceutical industry. Journal of Product Innovation Management, 21(4), 227–245.
8. Magazzini, L., Pammolli, F., & Riccaboni, M. (2016). Real Options and Incremental Search in Pharmaceutical R & D Project Portfolio Management. Creativity and Innovation Management, 25(2), 292–302.
9. Yeung, A. W. K., Atanasov, A. G., Sheridan, H., Klager, E., Eibensteiner, F., Vцlkl-Kernsock, S., ... & Schaden, E. (2021). Open innovation in medical and pharmaceutical research: a literature landscape analysis. Frontiers in Pharmacology, 11, 587526.
10. Chesbrough, H. W. (2003). Open innovation: The new imperative for creating and profiting from technology. Harvard Business Press.
11. Pisano, G. P. (2006). Science business: The promise, the reality, and the future of biotech. Harvard Business Press.
12. Schuhmacher, A., Germann, P. G., Trill, H., & Gassmann, O. (2013). Models for open innovation in the pharmaceutical industry. Drug discovery today, 18(23–24), 1133–1137.
13. Schuhmacher, A., Gassmann, O., Kwisda, S., Kremer, M., Hinder, M., & Hartl, D. (2025). The R&D productivity challenge: transforming the pharmaceutical ecosystem. Drug Discovery Today, 30(11), 1–6.
14. Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., ... & Yang, S. (2025). Artificial intelligence in drug development. Nature medicine, 31(1), 45–59.
15. Kulikova, O. M., & Suvorova, S. D. (2020). Pharmaceutical industry: main trends and challenges. Innovative Economy: Prospects for Development and Improvement, (4 (46)), 38–44 (In Russ.).
16. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature reviews Drug discovery, 9(3), 203–214.
17. Gunther McGrath, R., & Nerkar, A. (2004). Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms. Strategic Management Journal, 25(1), 1–21.
18. Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of translational medicine, 14(1), 105.
19. Ferreira, F. J., & Carneiro, A. S. (2025). AI-Driven Drug Discovery: A Comprehensive Review. ACS omega.
20. Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025). Applications of Artificial Intelligence in Drug Repurposing. Advanced Science, 12(14), 2411325.
21. Raza, M. A., Aziz, S., Noreen, M., Saeed, A., Anjum, I., Ahmed, M., & Raza, S. M. (2022). Artificial intelligence (AI) in pharmacy: an overview of innovations. INNOVATIONS in pharmacy, 13(2), 10-24926.
Review
For citations:
Rakhmanova K.R., Gorovoy А.А. Evolution of innovation management approaches in the R&D of pharmaceutical industry. Scientific notes of the Russian academy of entrepreneurship. 2026;25(2):73-83. (In Russ.) https://doi.org/10.24182/2073-6258-2026-25-2-73-83
JATS XML



























